MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
Healthcare
$10.79 +0.69%
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
52W Low $5.95High $62.75
Volume 1.32M
Average 0.99M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$244.83M
FY 2025 · Annual
Net Income
-$227.32M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.97K | 0 | 0 | 0 | 2.62M |
| Gross Profit | (4.97K) | 0 | 0 | 0 | (2.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.52M | 42.05M | 31.8M | 112.77M | 202.86M |
| Selling, General & Admin | 18.05M | 23.01M | 22.32M | 30.32M | 41.97M |
| Operating Expenses | 53.57M | 65.06M | 54.12M | 143.09M | 242.22M |
| Depreciation & Amortization | 4.97K | 164.78K | 370.32K | 1.38M | 2.62M |
| EBITDA | (53.63M) | (64.3M) | (43.61M) | (119.58M) | (219.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (53.58M) | (65.06M) | (54.12M) | (143.09M) | (244.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 7.25M |
| Other Income / Expenses | (61.85K) | 591.73K | 10.14M | 22.13M | 15.12M |
| Income Before Tax | (53.64M) | (64.47M) | (43.98M) | (120.96M) | (229.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 4.76K | 36.37K | 94.39K | 282.2K | 611K |
| Net Income | (53.64M) | (49.97M) | (36.01M) | (118.94M) | (227.32M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| EPS (Diluted) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| 36.93M | 29.36M | 49.12M | 62.87M | 64.46M | |
| 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
MLTX Earnings Waterfall · TTM
NASDAQ:MLTX · Revenue to Net Income
Key Ratios
EPS$-3.88
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$257.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.88, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Sep 30, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 |
How much revenue does MLTX generate?
MoonLake Immunotherapeutics (MLTX) reported $0.00 of revenue in fiscal 2025.
Is MLTX profitable?
MoonLake Immunotherapeutics (MLTX) reported -$227.32M of net income.
Continue the stock analysis
Jump to another research area for this company.